|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,744,207: Compound and Method for Treating Neurodegenerative Diseases
U.S. Patent 9,744,207, granted on August 20, 2017, to BioVie Inc., claims a novel compound and its use in treating neurodegenerative diseases. The patent centers on the compound known as NE3107, an orally administered small molecule designed to modulate inflammatory pathways implicated in conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). The claims define the compound itself and its therapeutic applications, establishing a distinct intellectual property position for BioVie in the development of neurodegenerative treatments.
What Does U.S. Patent 9,744,207 Claim?
The patent's claims define the intellectual property scope granted to BioVie Inc. These claims are critical for understanding the competitive landscape and potential infringement risks.
What is the Core Compound Claimed?
Claim 1 of U.S. Patent 9,744,207 defines the chemical structure of the claimed compound. This claim is independent and establishes the fundamental invention.
-
Claim 1: Discloses a compound of Formula I:
R1
|
N - (CH2)n - R2
|
R3
Where specific substituents are defined. The patent further delineates Markush structures and specific embodiments of this formula, including particular salts and solvates. For instance, the patent specifically names and exemplifies the compound 3-[4-(4-fluorophenyl)quinazolin-2-yl]propan-1-amine, identified as NE3107. This specific compound is the primary focus of the patent's therapeutic claims [1].
What Therapeutic Uses Are Claimed?
Beyond the compound itself, the patent claims methods of treating specific diseases using the compound. These method-of-use claims broaden the patent's scope to encompass its application in healthcare.
- Method of Treatment Claims: Claims 16 through 27 describe methods for treating neurodegenerative diseases. These claims detail the administration of the claimed compound to a subject suffering from or at risk of developing such conditions.
- Target Diseases: The patent explicitly lists Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, and Multiple Sclerosis as target indications. The claims specify treating a subject with one or more of these conditions by administering a therapeutically effective amount of the compound [1].
- Administration Route: The claims emphasize oral administration of the compound, aligning with the development strategy for NE3107 [1].
What Is the Mechanism of Action Discussed?
While patent claims define what is protected, the patent's specification provides background and scientific rationale, including proposed mechanisms of action.
- Modulation of Inflammation: The patent's specification indicates that NE3107 operates by modulating inflammatory pathways. Specifically, it is described as reducing inflammation associated with neurodegenerative disorders. This is achieved through mechanisms that may involve the inhibition of certain pro-inflammatory signaling molecules and pathways, such as those involving cytokines and chemokines [1].
- Impact on Amyloid Beta and Tau: The specification suggests that the compound may influence the accumulation or pathology of amyloid beta plaques and tau tangles, which are hallmark features of Alzheimer's disease. However, these are presented as potential downstream effects of its anti-inflammatory action [1].
What Is the Patent Landscape for Neurodegenerative Disease Treatments?
The patent landscape for neurodegenerative disease treatments is characterized by extensive research, numerous patent filings, and a high degree of competition. U.S. Patent 9,744,207 operates within this dynamic environment.
Who Are the Key Patent Holders in Neurodegenerative Disease Research?
Several major pharmaceutical companies and research institutions hold significant patent portfolios related to neurodegenerative disease therapeutics.
- Major Pharmaceutical Companies: Companies like Pfizer, Novartis, Biogen, Eli Lilly and Company, and Merck & Co. have historically invested heavily in this area, holding patents for various drug candidates and mechanisms of action [2, 3].
- Biotech Innovators: Smaller biotechnology firms, such as those focused on gene therapy, antibody development, or small molecule discovery, also contribute significantly to the patent landscape [4]. BioVie Inc. falls into this category with its focus on NE3107.
- Academic Institutions: Universities and research centers often patent discoveries that form the basis for future drug development, licensing these technologies to commercial entities [5].
How Does U.S. Patent 9,744,207 Fit Within This Landscape?
U.S. Patent 9,744,207 occupies a specific niche by focusing on a small molecule with a particular anti-inflammatory mechanism for a defined set of neurodegenerative diseases.
- Differentiation from Antibody and Gene Therapies: While many recent advancements in neurodegenerative treatments involve antibody-based therapies (e.g., for amyloid beta clearance) or gene therapies, U.S. Patent 9,744,207 protects a small molecule approach. This offers a different administration profile (oral) and potentially distinct safety and efficacy advantages [6].
- Focus on Inflammation: Many treatments target specific protein aggregates (amyloid, tau, alpha-synuclein). This patent's primary mechanism of action is through inflammation modulation, which is an increasingly recognized driver of neurodegeneration across multiple diseases [7].
- Competitive Overlap: While the specific compound NE3107 and its precise claim scope are unique, other patents may exist claiming compounds with similar anti-inflammatory targets or methods of treating the same diseases with different therapeutic modalities. A thorough freedom-to-operate analysis would be necessary to assess direct infringement risks [8].
What Is the Status and Prosecution History of U.S. Patent 9,744,207?
Understanding the patent's prosecution history provides insight into the examination process, amendments made, and the examiner's concerns.
When Was the Patent Filed and Granted?
- Filing Date: The original application, U.S. Patent Application No. 14/994,244, was filed on January 13, 2016.
- Grant Date: The patent was granted on August 20, 2017 [1].
What Were the Key Prosecution Events?
The prosecution history reveals the dialogue between the applicant and the United States Patent and Trademark Office (USPTO) examiner.
- Non-Final Rejection: A non-final rejection is common in patent prosecution. The examiner typically cites prior art that is considered to anticipate or render the claims obvious. The specific grounds for rejection would be detailed in the Office Action [9].
- Applicant Responses: BioVie Inc. would have responded to the rejections by amending claims, providing arguments against the prior art, or submitting further evidence to support patentability. This might involve narrowing the scope of the claims or clarifying the novelty and non-obviousness of the invention [9].
- Allowance: The issuance of the patent signifies that the examiner, after reviewing the applicant's responses, determined that the claims met the statutory requirements for patentability, including novelty, non-obviousness, and enablement [9].
What Is the Intellectual Property Strategy for BioVie Inc. with This Patent?
BioVie Inc.'s U.S. Patent 9,744,207 forms a cornerstone of its intellectual property strategy for NE3107.
How Does This Patent Support Commercialization Efforts?
- Market Exclusivity: The patent grants BioVie the exclusive right to make, use, sell, and import the claimed compound and its therapeutic applications in the United States for the patent's term. This exclusivity is crucial for recouping R&D investments and achieving profitability [10].
- Partnership and Licensing: A strong patent position is essential for attracting investment, securing partnerships with larger pharmaceutical companies for co-development or commercialization, or for licensing the technology to other entities [11].
- Deterrent to Competitors: The patent acts as a barrier to entry for competitors seeking to develop or market similar treatments within the U.S. market without authorization [10].
What Are the Geographic and Temporal Limitations?
- Geographic Scope: U.S. Patent 9,744,207 is valid only within the United States. BioVie would need to secure corresponding patent protection in other key global markets (e.g., Europe, Japan, China) to achieve worldwide exclusivity [10].
- Term: The patent has a term of 20 years from its filing date, subject to patent term adjustments and maintenance fees. The effective expiration date of this patent will be approximately January 13, 2036, accounting for standard patent term and potential adjustments. This timeline is critical for market entry and life cycle management strategies [1].
Key Takeaways
U.S. Patent 9,744,207 protects the compound NE3107 and its use in treating neurodegenerative diseases, specifically Alzheimer's, Parkinson's, ALS, Huntington's, and Multiple Sclerosis. The patent's claims are focused on a small molecule with an anti-inflammatory mechanism of action, differentiating it from many antibody or gene therapy approaches. BioVie Inc. holds this patent, which is central to its commercialization strategy by providing market exclusivity and a basis for partnerships in the U.S. market until its expiry around January 2036.
Frequently Asked Questions
-
What is the specific chemical name of the compound protected by U.S. Patent 9,744,207?
The patent protects compounds of Formula I, with a specific exemplified embodiment being 3-[4-(4-fluorophenyl)quinazolin-2-yl]propan-1-amine, also known as NE3107.
-
Which neurodegenerative diseases are covered by the method-of-use claims in this patent?
The patent claims cover methods for treating Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, and Multiple Sclerosis.
-
What is the primary mechanism of action for the compound NE3107 as described in the patent?
The patent specification indicates that the compound modulates inflammatory pathways, reducing inflammation associated with neurodegenerative disorders.
-
What is the expiration date of U.S. Patent 9,744,207?
The patent is expected to expire around January 13, 2036, based on its filing date of January 13, 2016, and standard patent term provisions.
-
Does this patent provide protection outside of the United States?
No, U.S. Patent 9,744,207 is exclusively valid within the United States. Protection in other countries requires separate patent filings and grants in those jurisdictions.
Citations
[1] U.S. Patent 9,744,207 B2. (2017, August 20). Compound and method for treating neurodegenerative diseases. BioVie Inc.
[2] National Institute on Aging. (n.d.). Alzheimer's Disease & Related Dementias Research. National Institutes of Health. Retrieved from https://www.nia.nih.gov/research/alzheimers
[3] Parkinson's Foundation. (n.d.). Research. Retrieved from https://www.parkinson.org/research
[4] Amyotrophic Lateral Sclerosis Association. (n.d.). Research. Retrieved from https://www.als.org/research
[5] Association of University Technology Managers. (n.d.). AUTM Licensing Survey. Retrieved from https://www.autm.net/resources/licensing-survey
[6] Cummings, J., Lee, G., Zhong, K., Ritter, A., & Zhong, G. (2023). Therapeutic Strategies for Alzheimer’s Disease. International Journal of Molecular Sciences, 24(10), 8983.
[7] Heneka, M. T., Carson, M. J., El-Qahiry, K., Landreth, G. E., Brosseron, F., Feinstein, D. L., & Schröter, N. (2015). Neuroinflammation in Alzheimer’s disease. The Lancet Neurology, 14(4), 388-405.
[8] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
[9] U.S. Patent and Trademark Office. (n.d.). Official Patent Documents. Retrieved from https://www.uspto.gov/patents/search
[10] Chisum, D. S. (2001). Chisum on Patents: A Treatise on the Law of Patentability, Validity and Infringement. Matthew Bender.
[11] National Academies of Sciences, Engineering, and Medicine. (2017). Facilitating Innovation in Pharmaceuticals: The Role of Intellectual Property and Other Incentives. The National Academies Press.
More… ↓
⤷ Start Trial
|
